Meletios A. Dimopoulos

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

2017 | 1. lékařská fakulta

Publikace